KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Gains from Investment Securities: 2009-2024

Historic Gains from Investment Securities for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $80.6 million.

  • Halozyme Therapeutics' Gains from Investment Securities fell 107.14% to -$307,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $78.4 million, marking a year-over-year increase of 136.44%. This contributed to the annual value of $80.6 million for FY2024, which is 153.87% up from last year.
  • Latest data reveals that Halozyme Therapeutics reported Gains from Investment Securities of $80.6 million as of FY2024, which was up 153.87% from $31.8 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Gains from Investment Securities ranged from a high of $80.6 million in FY2024 and a low of $1.5 million during FY2021.
  • Its 3-year average for Gains from Investment Securities is $48.9 million, with a median of $34.4 million in 2022.
  • As far as peak fluctuations go, Halozyme Therapeutics' Gains from Investment Securities crashed by 63.68% in 2021, and later spiked by 2,201.80% in 2022.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Gains from Investment Securities stood at $4.1 million in 2020, then slumped by 63.68% to $1.5 million in 2021, then skyrocketed by 2,201.80% to $34.4 million in 2022, then dropped by 7.78% to $31.8 million in 2023, then soared by 153.87% to $80.6 million in 2024.